Abstract
MMPs are a family of Zn dependent endopeptidases, which can mediate degradation of ECM components during various physiological and pathological processes including cancer. Some ECM components, through interaction with integrin receptor and modulation of downstream signaling, are capable of regulating expression and activity of several MMPs. α5β1 integrin is the universally accepted receptor for the ECM component fibronectin (FN). The present review deals with the downstream signaling involved in the α5β1 integrin mediated modulation of expression and activity of MMPs and their effector responses in different cellular system.
Keywords: ECM, Fibronectin, Integrin, MMP, extracellular matrix, matrix metalloproteinase, membrane-type-1 MMP, tissue inhibitor of metalloproteinases, focal adhesion kinase, phosphatidyl-inositol-3-kinase, mitogen activated protein kinase, extracellular regulated kinase.
Anti-Cancer Agents in Medicinal Chemistry
Title:Modulation of MMPs by Cell Surface Integrin Receptor α5β1
Volume: 12 Issue: 7
Author(s): Sekhar Pal, Kirat Kumar Ganguly, Shuvojit Moulik and Amitava Chatterjee
Affiliation:
Keywords: ECM, Fibronectin, Integrin, MMP, extracellular matrix, matrix metalloproteinase, membrane-type-1 MMP, tissue inhibitor of metalloproteinases, focal adhesion kinase, phosphatidyl-inositol-3-kinase, mitogen activated protein kinase, extracellular regulated kinase.
Abstract: MMPs are a family of Zn dependent endopeptidases, which can mediate degradation of ECM components during various physiological and pathological processes including cancer. Some ECM components, through interaction with integrin receptor and modulation of downstream signaling, are capable of regulating expression and activity of several MMPs. α5β1 integrin is the universally accepted receptor for the ECM component fibronectin (FN). The present review deals with the downstream signaling involved in the α5β1 integrin mediated modulation of expression and activity of MMPs and their effector responses in different cellular system.
Export Options
About this article
Cite this article as:
Pal Sekhar, Kumar Ganguly Kirat, Moulik Shuvojit and Chatterjee Amitava, Modulation of MMPs by Cell Surface Integrin Receptor α5β1, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (7) . https://dx.doi.org/10.2174/187152012802650183
DOI https://dx.doi.org/10.2174/187152012802650183 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Control of Protein Synthesis in Malignant Transformation - the Role of eIF4E and the eIF4E Binding Proteins in the Regulation of Apoptosis
Current Cancer Therapy Reviews Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Recent Advances in Biotransformation by Cunninghamella Species
Current Drug Metabolism Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy
Current Medicinal Chemistry Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Current Topics in Medicinal Chemistry The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs
Current Drug Targets - Infectious Disorders Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry The Human Trypanolytic Factor: A Drug Shaped Naturally
Infectious Disorders - Drug Targets